Hsing-Tao Kuo

Hsing-Tao Kuo

Auto-generated profile, based on publicly available information

Hsing-Tao Kuo

Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
Pei Chien TsaiPei Chien Tsai
Pei Chien Tsai
HKHsing-Tao Kuo
Hsing-Tao Kuo
CHChao-Hung Hung
Chao-Hung Hung
KTKuo-Chih Tseng
Kuo-Chih Tseng
HLHsueh-Chou Lai
Hsueh-Chou Lai
MYMing-Lung Yu
Ming-Lung Yu

2 March 2021 in Liver International
Verified
Journal Article
Open access
PDF file
CCChi-Yi Chen
Chi-Yi Chen
CHChung-Feng Huang
Chung-Feng Huang
PCPin-Nan Cheng
Pin-Nan Cheng
KTKuo-Chih Tseng
Kuo-Chih Tseng
CLChing-Chu Lo
Ching-Chu Lo
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
Background/aims: Direct‐acting antivirals (DAAs) are highly effective in treating chronic hepatitis C virus (HCV)‐infected patients. The real‐world treatment outcome in Taiwanese patients on a nationwide basis is elusive.Methods: The Taiwan HCV Registry (TACR) programme is a nationwide registry platform including 48 study sites, which is organized and supervised by the Taiwan Association for the Study of the Liver. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA 12 weeks after end‐of‐treatment).Results: A total of 13 951 registered patients with SVR12 data available were analysed (mean age, 63.0 years; female, 55.9%; HCV genotype‐1 [GT1], 57.9%; cirrhosis, 38.4%; preexisting hepatocellular carcinoma [HCC], 10.6%; and hepatitis B virus coinfection, 7.7%). The overall SVR12 rate was 98.3%, with 98.7%, 98.0%, 98.4% and 97.4% in treatment‐naïve noncirrhotic, treatment‐naïve cirrhotic, treatment‐experienced noncirrhotic and treatment‐experienced cirrhotic patients, respectively. The SVR12 rate was > 95% across all subgroups except treatment‐experienced cirrhotic patients who received sofosbuvir/ribavirin (88.7%), treatment‐naïve noncirrhotic patients (94.8%) and treatment‐experienced cirrhotic (94.8%) patients who received daclatasvir/asunaprevir. The most important factor associated with treatment failure was DAA adherence < 60% ( adjusted odds ratio [aOR]/95% confidence interval [CI]: 117.1/52.4‐261.3, P < .001), followed by GT3/GT2 (aOR/CI: 5.78/2.25‐14.9, P = .0003 and aOR/CI: 1.55/1.05‐2.29, P = .03, compared with GT1), active hepatocellular carcinoma (aOR/CI: 4.29/2.57‐7.16, P < .001), the use of sofosbuvir/ribavirin (aOR/CI: 2.51/1.67‐3.77, P < .001) and daclatasvir/asunaprevir (aOR/CI: 3.29/1.94‐5.58, P < .001), decompensated liver cirrhosis (aOR/CI: 2.50/1.20‐5.22, P = .02) and high HCV viral loads (aOR/CI: 2.16/1.57‐2.97, P < .001).Conclusions: DAAs are highly effective in treating Taiwanese HCV patients in the real‐world setting. Maintaining DAA adherence and selecting highly efficacious regimens are keys to ensure treatment success.

12 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JQJenny Que
Jenny Que
HKHsing-Tao Kuo
Hsing-Tao Kuo
LLLi-Ching Lin
Li-Ching Lin
KLKuei-Li Lin
Kuei-Li Lin
CLChia-Hui Lin
Chia-Hui Lin
Ching-Chieh YangChing-Chieh Yang
Ching-Chieh Yang
Stereotactic body radiation therapy (SBRT) has been an emerging non-invasive treatment modality for patients with hepatocellular carcinoma (HCC) when curative treatments cannot be applied. In this study, we report our clinical experience with Cyberknife SBRT for unresectable HCC and evaluate the efficacy and clinical outcomes of this highly sophisticated treatment technology. Between 2008 and 2012, 115 patients with unresectable HCC treated with Cyberknife SBRT were retrospectively analyzed. Doses ranged from 26 Gy to 40 Gy were given in 3 to 5 fractions for 3 to 5 consecutive days. The cumulative probability of survival was calculated according to the Kaplan-Meier method and compared using log-rank test. Univariate and multivariate analysis were performed using Cox proportional hazard models. The median follow-up was 15.5 months (range, 2-60 months). Based on Response Evaluation and Criteria in Solid Tumors (RECIST). We found that 48.7 % of patients achieved a complete response and 40 % achieved a partial response. Median survival was 15 months (4-25 months). Overall survival (OS) at 1- and 2-years was 63.5 %(54-71.5 %) and 41.3 % (31.6-50.6 %), respectively, while 1- and 2- years Progression-free Survival (PFS) rates were 42.8 %(33.0-52.2 %) and 38.8 % (29.0-48.4 %). Median progression was 6 months (3-16 months). In-field recurrence free survival at 1 and 2 years was 85.3 % (76.2-91.1 %) and 81.6 % (72.2-88.6 %), respectively, while the 1- and 2-years out-field recurrence free survival were 52.5 % (41.2-60.8 %) and 49.5 %(38.9-59.2 %), respectively. Multivariate analysis revealed that Child-Pugh score (A vs. B), Portal vein tumor thrombosis (positive vs. negative), Tumor size (≤4 cm vs >4-9 cm /≥10 cm), and tumor response after SBRT (CR vs. PR/stable) were independent predictors of OS. Acute toxicity was mostly transient and tolerable. Cyberknife SBRT appears to be an effective non-invasive treatment for local unresectable HCC with low risk of severe toxicity. These results suggested that Cyberknife SBRT can be a good alternative treatment for unresectable HCC unsuitable for standard treatment.

1 September 2006 in Translational Research
Verified
Journal Article
Closed access
PDF file
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
WCWan-Long Chuang
Wan-Long Chuang
CDChia-Yen Dai
Chia-Yen Dai
LLLi-Po Lee
Li-Po Lee
ZLZu-Yau Lin
Zu-Yau Lin
HKHsing-Tao Kuo
Hsing-Tao Kuo

27 November 2024 in Hepatology International
Verified
Journal Article
Closed access
PDF file
CKChia-Chih Kuo
Chia-Chih Kuo
MCMin-Hsiang Chuang
Min-Hsiang Chuang
CLChun-Hsien Li
Chun-Hsien Li
PHPo-Yu Huang
Po-Yu Huang
HKHsing-Tao Kuo
Hsing-Tao Kuo
CLChih-Cheng Lai
Chih-Cheng Lai

1 March 2021 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
SHShih-Jer Hsu
Shih-Jer Hsu
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
CSChien-Wei Su
Chien-Wei Su
CPCheng-Yuan Peng
Cheng-Yuan Peng
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien
WCWan-Long Chuang
Wan-Long Chuang
Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to the 8 to 14 isomers of other on-market pegylated interferon products, allowing every-two-week injection with high tolerability. It received European Medicines Agency marketing authorization in 2019 and Taiwan Biologics License Applications Approval in 2020 for the treatment of polycythemia vera. This study aimed to evaluate the safety and efficacy of Ropeginterferon alfa-2b plus ribavirin in genotype 2 chronic hepatitis C (CHC) patients. Eighty-six treatment naive patients with genotype 2 CHC were randomized to weekly peginterferon alfa-2a (Peg-IFN-α2a) at 180 μg (n = 22), or every-two-week Ropeginterferon alfa-2b at 270 μg (n = 23), 360 μg (n = 21), 450 μg (n = 20), plus daily oral ribavirin 1000 mg (≤75 kg) or 1200 mg (>75 kg). Patients with rapid virologic response received 16-week regimen while those without RVR received 24-week regimen. The primary endpoint was sustained virologic response at 24 weeks post-treatment (SVR24). SVR24 was achieved by 95.5%, 78.3%, 85.7%, and 60% of subjects in Peg-IFN-α2a 180 μg, Ropeginterferon alfa-2b 270 μg, 360 μg, and 450 μg groups, respectively. The safety profile was similar across 4 groups. The incidence rate of adverse event during the treatment period was 0.407, 0.252, 0.395, and 0.347 per patient-week, respectively. Ropeginterferon alfa-2b, although at only half the number of injections, is as safe and effective as Peg-IFN-α2a for genotype 2 CHC. A phase 3 study to confirm safety and efficacy of Ropeginterferon alfa-2b in genotype 2 CHC is ongoing.